Urine Cell-Free MicroRNAs in Localized Prostate Cancer Patients

Prostate cancer (PCa) is the most common cancer in men. Prostate-specific antigen screening is recommended for the detection of PCa. However, its specificity is limited. Thus, there is a need to find more reliable biomarkers that allow non-invasive screening for early-stage PCa. This study aims to e...

Full description

Bibliographic Details
Main Authors: Yoko Koh, Matias A. Bustos, Jamie Moon, Rebecca Gross, Romela Irene Ramos, Suyeon Ryu, Jane Choe, Selena Y. Lin, Warren M. Allen, David L. Krasne, Timothy G. Wilson, Dave S. B. Hoon
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/10/2388
Description
Summary:Prostate cancer (PCa) is the most common cancer in men. Prostate-specific antigen screening is recommended for the detection of PCa. However, its specificity is limited. Thus, there is a need to find more reliable biomarkers that allow non-invasive screening for early-stage PCa. This study aims to explore urine microRNAs (miRs) as diagnostic biomarkers for PCa. We assessed cell-free miR (cfmiR) profiles of urine and plasma samples from pre- and post-operative PCa patients (<i>n</i> = 11) and normal healthy donors (16 urine and 24 plasma) using HTG EdgeSeq miRNA Whole Transcriptome Assay based on next-generation sequencing. Furthermore, tumor-related miRs were detected in formalin-fixed paraffin-embedded tumor tissues obtained from patients with localized PCa. Specific cfmiRs signatures were found in urine samples of localized PCa patients using differential expression analysis. Forty-two cfmiRs that were detected were common to urine, plasma, and tumor samples. These urine cfmiRs may have potential utility in diagnosing early-stage PCa and complementing or improving currently available PCa screening assays. Future studies may validate the findings.
ISSN:2072-6694